Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor

Kazushi Tanimoto, MD PhD, Hiroshi Fujiwara, MD PhD, Isao Tawara, MD PhD, Masahiro Masuya, MD PhD, Shinichi Kageyama, MD PhD, Tetsuya Nishida, MD PhD, Makoto Murata, MD PhD, Seitaro Terakura, MD PhD, Yoshiki Akatsuka, MD PhD, Hiroaki Ikeda, MD PhD, Yoshihiro Miyahara, MD PhD, Ikuei Nukaya, PhD, Kazutoh Takesako, PhD, Nobuhiko Emi, MD PhD, Naoyuki Katayama, MD PhD, Hiroshi Shiku, MD PhD, Masaki Yasukawa, MD PhD

Blood (2016) 128 (22): 1653.

https://doi.org/10.1182/blood.V128.22.1653.1653

Published: 2016

Journal Articles

Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule

Hiroaki Ikeda, MD PhD, Yasushi Akahori, PhD, Motohiro Yoneyama, Yuki Orito, Yoshihiro Miyahara, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno, PhD, Kazutoh Takesako, PhD, Hiroshi Fujiwara, MD PhD, Masaki Yasukawa, MD PhD, Hiroshi Shiku, MD PhD

Blood (2015) 126 (23): 4292.

https://doi.org/10.1182/blood.V126.23.4292.4292

Published: 2015

Journal Articles

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Isao Tawara, MD PhD, Masahiro Masuya, MD PhD, Shinichi Kageyama, MD PhD, Tetsuya Nishida, MD PhD, Seitaro Terakura, MD PhD, Makoto Murata, MD PhD, Hiroshi Fujiwara, MD PhD, Yoshiki Akatsuka, MD PhD, Hiroaki Ikeda, MD PhD, Yoshihiro Miyahara, MD PhD, Daisuke Tomura, PhD, Ikuei Nukaya, PhD, Kazutoh Takesako, PhD, Nobuhiko Emi, MDPhD, Masaki Yasukawa, MD PhD, Naoyuki Katayama, MD PhD, Hiroshi Shiku, MD PhD

Blood (2015) 126 (23): 97.

https://doi.org/10.1182/blood.V126.23.97.97

Published: 2015

Journal Articles

Engineering of CD19-CAR T Cells from Non-Hodgkin Lymphoma Patients in a Closed System in Combination with Retronectin/OKT3 Stimulation

Hideto Chono, PhD, Kenichi Tahara, PhD, Ikuei Nukaya, PhD, Junichi Mineno, PhD, Eisuke Uehara, MD PhD, Tomonori Tsukahara, PhD, Ken Ohmine, MD PhD, Keiya Ozawa, MD PhD, Kazutoh Takesako, PhD

Blood (2014) 124 (21): 2446.

https://doi.org/10.1182/blood.V124.21.2446.2446

Published: 2014

Journal Articles

Tumor-Specific TCR-Engineered Donor Lymphocyte Infusion Therapy with Reduced GvHD Induction Utilizing Novel Retrovirus Vector Silencing Endogenous TCR Expression

Hiroaki Ikeda, MD PhD, Hiroaki Ueno, Isao Tawara, MD, PhD, Ayumi Kawamura, Naoko Imai, MD PhD, Sachiko Okamoto, PhD, Junichi Mineno, PhD, Kazutoh Takesako, PhD, Naoyuki Katayama, MD PhD, Hiroshi Shiku, MD PhD

Blood (2014) 124 (21): 656.

https://doi.org/10.1182/blood.V124.21.656.656

Published: 2014

NARROW

Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor

Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Engineering of CD19-CAR T Cells from Non-Hodgkin Lymphoma Patients in a Closed System in Combination with Retronectin/OKT3 Stimulation

Tumor-Specific TCR-Engineered Donor Lymphocyte Infusion Therapy with Reduced GvHD Induction Utilizing Novel Retrovirus Vector Silencing Endogenous TCR Expression

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor

Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Engineering of CD19-CAR T Cells from Non-Hodgkin Lymphoma Patients in a Closed System in Combination with Retronectin/OKT3 Stimulation

Tumor-Specific TCR-Engineered Donor Lymphocyte Infusion Therapy with Reduced GvHD Induction Utilizing Novel Retrovirus Vector Silencing Endogenous TCR Expression

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only